NFKB1 and Miyoshi myopathy: It has been previously shown that the co-administration of ibrutinib with bortezomib increased cytotoxicity in bortezomib-resistant MCL and DLBCL cells; however, the NF-kB inducing effet of bortezomib has only been observed in MM and may be linked to the highly developed protein biosynthesis machinery of MM cells [18].